|
|
Article: Grant Gives Alnylam $23M For Anti-Ebola Virus Work.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
For the second time in about a week, the feds tapped a biotech firm for research into hemorrhagic fever virus, including Ebola, and Alnylam Pharmaceuticals Inc. stands to gain $23 million over the next four years from the anti-terror contract.
Cambridge, Mass.-based Alnylam is putting its expertise in small interfering RNAs to work on the project, and establishing Alnylam Biodefense, through which the firm plans to build a platform for RNAi drugs against potential bioterrorism.
"[Defense experts] do believe Ebola is a potentially weaponizable virus," said Zachary Zimmerman, director of external alliances for Alnylam, who was ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|